ATE427951T1 - Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren - Google Patents

Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren

Info

Publication number: ATE427951T1
Authority: AT; Austria
Prior art keywords: sup; alkyl; hydrogen; cycloalkyl; haloalkyl
Prior art date: 2002-11-18

Application number

AT03775346T

Other languages

English (en)

Inventor

Jian Chen

Kin-Chun Luk

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-18

Filing date

2003-11-12

Publication date

2009-04-15

2003-11-12 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2009-04-15 Application granted granted Critical

2009-04-15 Publication of ATE427951T1 publication Critical patent/ATE427951T1/de

Links

229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 7
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
125000000753 cycloalkyl group Chemical group 0.000 abstract 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
125000001188 haloalkyl group Chemical group 0.000 abstract 3
150000002431 hydrogen Chemical class 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
125000004966 cyanoalkyl group Chemical group 0.000 abstract 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
125000004663 dialkyl amino group Chemical group 0.000 abstract 2
125000004404 heteroalkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
239000012826 P38 inhibitor Substances 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)

AT03775346T 2002-11-18 2003-11-12 Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren ATE427951T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42765202P	2002-11-18	2002-11-18

Publications (1)

Publication Number	Publication Date
ATE427951T1 true ATE427951T1 (de)	2009-04-15

Family

ID=32326577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03775346T ATE427951T1 (de)	2002-11-18	2003-11-12	Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren

Country Status (14)

Country	Link
US (2)	US6943158B2 (de)
EP (1)	EP1565475B1 (de)
JP (1)	JP2006514624A (de)
KR (1)	KR20050075028A (de)
CN (1)	CN100357293C (de)
AT (1)	ATE427951T1 (de)
AU (1)	AU2003283393A1 (de)
BR (1)	BR0316375A (de)
CA (1)	CA2506565A1 (de)
DE (1)	DE60327097D1 (de)
MX (1)	MXPA05005028A (de)
PL (1)	PL377620A1 (de)
RU (1)	RU2340618C2 (de)
WO (1)	WO2004046152A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2584507C (en) *	2004-10-20	2016-04-26	Resverlogix Corp.	Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
EP2314295B1 (de) *	2005-07-29	2015-01-28	Resverlogix, Inc	Arzneimittel zur Prävention und Behandlung komplexer Erkrankungen und deren Freisetzung mittels einsetzbarer Medizinprodukte
JPWO2008001929A1 (ja) *	2006-06-28	2009-12-03	あすか製薬株式会社	炎症性腸疾患の処置剤
EP1918284A1 (de) *	2006-10-30	2008-05-07	Glaxo Group	Hydrazinopyrimidine als Cysteine Protease Inhibitoren
CA2676984C (en)	2007-02-01	2015-03-17	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular diseases
CA2711103C (en)	2008-06-26	2016-08-09	Resverlogix Corp.	Methods of preparing quinazolinone derivatives
DE102008063561A1 (de) *	2008-12-18	2010-08-19	Bayer Cropscience Ag	Hydrazide, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Insektizide
AU2010204106B2 (en)	2009-01-08	2014-05-08	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular disease
EP2400985A2 (de)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors
JP2012519281A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010106436A2 (en)	2009-03-18	2010-09-23	Resverlogix Corp.	Novel anti-inflammatory agents
AU2010239266B2 (en)	2009-04-22	2015-01-22	Resverlogix Corp.	Novel anti-inflammatory agents
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
CA2851996C (en)	2011-11-01	2020-01-07	Resverlogix Corp.	Pharmaceutical compositions for substituted quinazolinones
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
HRP20170430T1 (hr)	2012-06-13	2017-06-16	Incyte Holdings Corporation	Supstituirani triciklični spojevi kao inhibitori fgfr
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
WO2014080290A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9271978B2 (en)	2012-12-21	2016-03-01	Zenith Epigenetics Corp.	Heterocyclic compounds as bromodomain inhibitors
PL2986610T4 (pl) *	2013-04-19	2019-06-28	Incyte Holdings Corporation	Bicykliczne heterocykle jako inhibitory FGFR
CN103757026B (zh) *	2013-12-20	2017-04-05	广州圣露生物技术有限公司	FGFR2b胞外段的基因序列、多肽及其应用
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MY197720A (en)	2015-02-20	2023-07-10	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2016147053A1 (en)	2015-03-13	2016-09-22	Resverlogix Corp.	Compositions and therapeutic methods for the treatment of complement-associated diseases
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
NZ762856A (en)	2017-10-05	2020-07-31	Fulcrum Therapeutics Inc	P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
JP7568512B2 (ja)	2018-05-04	2024-10-16	インサイト・コーポレイション	Ｆｇｆｒ阻害剤の塩
BR112020022392A2 (pt)	2018-05-04	2021-02-02	Incyte Corporation	formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP7675711B2 (ja)	2019-10-14	2025-05-13	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
PE20221504A1 (es)	2019-12-04	2022-09-30	Incyte Corp	Derivados de un inhibidor de fgfr
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352060A1 (de)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclische heterocyclen als fgfr-inhibitoren
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1353534A (en)	1971-07-13	1974-05-22	Roche Products Ltd	Pyrimidotriazines and a process for the manufacture thereof
US4025510A (en) *	1975-12-01	1977-05-24	E. I. Du Pont De Nemours And Company	2,4-Diaryl[1,3,4H]thiadiazines fused to quinoxalines
RU2265606C2 (ru) *	1999-10-21	2005-12-10	Ф.Хоффманн-Ля Рош Аг	ГЕТЕРОАЛКИЛАМИНОЗАМЕЩЕННЫЕ БИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ГЕТЕРОЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ р38
JP4141830B2 (ja) *	2000-08-31	2008-08-27	エフ．ホフマン−ラロシュアーゲー	細胞増殖の阻害剤としての７−オキソ−ピリドピリミジン類
US6642381B2 (en) *	2001-12-27	2003-11-04	Hoffman-La Roche Inc.	Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors

2003
- 2003-11-12 CA CA002506565A patent/CA2506565A1/en not_active Abandoned
- 2003-11-12 EP EP03775346A patent/EP1565475B1/de not_active Expired - Lifetime
- 2003-11-12 BR BR0316375-0A patent/BR0316375A/pt not_active IP Right Cessation
- 2003-11-12 AT AT03775346T patent/ATE427951T1/de not_active IP Right Cessation
- 2003-11-12 MX MXPA05005028A patent/MXPA05005028A/es active IP Right Grant
- 2003-11-12 DE DE60327097T patent/DE60327097D1/de not_active Expired - Fee Related
- 2003-11-12 KR KR1020057008919A patent/KR20050075028A/ko not_active Ceased
- 2003-11-12 PL PL377620A patent/PL377620A1/pl not_active Application Discontinuation
- 2003-11-12 RU RU2005119281/04A patent/RU2340618C2/ru not_active IP Right Cessation
- 2003-11-12 WO PCT/EP2003/012652 patent/WO2004046152A1/en not_active Ceased
- 2003-11-12 AU AU2003283393A patent/AU2003283393A1/en not_active Abandoned
- 2003-11-12 JP JP2004552580A patent/JP2006514624A/ja active Pending
- 2003-11-12 CN CNB2003801035760A patent/CN100357293C/zh not_active Expired - Fee Related
- 2003-11-18 US US10/715,666 patent/US6943158B2/en not_active Expired - Fee Related
2005
- 2005-07-27 US US11/190,292 patent/US20050261284A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1565475B1 (de)	2009-04-08
DE60327097D1 (de)	2009-05-20
US6943158B2 (en)	2005-09-13
RU2340618C2 (ru)	2008-12-10
PL377620A1 (pl)	2006-02-06
AU2003283393A1 (en)	2004-06-15
WO2004046152A1 (en)	2004-06-03
MXPA05005028A (es)	2005-08-03
US20040097493A1 (en)	2004-05-20
KR20050075028A (ko)	2005-07-19
JP2006514624A (ja)	2006-05-11
BR0316375A (pt)	2005-10-04
US20050261284A1 (en)	2005-11-24
CN100357293C (zh)	2007-12-26
RU2005119281A (ru)	2006-03-20
EP1565475A1 (de)	2005-08-24
CN1714093A (zh)	2005-12-28
CA2506565A1 (en)	2004-06-03

Legal Events

Date	Code	Title	Description
2009-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE427951T1 (de)	2009-04-15	Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren
AR040787A1 (es)	2005-04-20	6-alcoxi-piridopirimidinas
ATE265432T1 (de)	2004-05-15	3-amino-5-carboxy-substituierte piperidine und 3- amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten
DE60023318D1 (de)	2006-03-02	Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
NZ509939A (en)	2002-08-28	1H-imidazopyridine derivatives useful as TNF or IL-1 inhibitors
PT1022272E (pt)	2004-08-31	Compostos heterociclicos fundidos substituidos
ATE190625T1 (de)	2000-04-15	Antagonisten gegen den thrombinrezeptor
EA200600509A1 (ru)	2006-08-25	Соединения пиримидотиофена
DK0873123T3 (da)	2003-08-04	Inhibitorer af protein-isoprenyltransferaser
ATE206412T1 (de)	2001-10-15	Heterocyclische verbindungen als bradykinin antagonisten
ATE37375T1 (de)	1988-10-15	Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva.
DK0781766T3 (da)	2004-07-26	Heterocyclisk derivat og medikament
RU2010154425A (ru)	2012-07-20	Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека
KR960702444A (ko)	1996-04-27	3-아미노아제핀 화합물 및 그 의약 용도(3-aminoazepine compound and pharmaceutical use thereof)
RU97103983A (ru)	1999-04-10	Лекарственные композиции и производные триазина
DE69924292D1 (de)	2005-04-21	Pyrazol verbindungen und ihre verwendung
ATE307812T1 (de)	2005-11-15	Imidazopyridinverbindungen als 5-ht4- rezeptormodulatoren
KR900004693A (ko)	1990-04-12	피리딘 화합물 및 그의 약제학적 용도
DE69017593D1 (de)	1995-04-13	Substituierte N-(Imidazolyl)alkyl-alanin-Derivate.
ATE324890T1 (de)	2006-06-15	Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
ATE505462T1 (de)	2011-04-15	Neue biologischaktive molekü le
ATE449782T1 (de)	2009-12-15	Adenosin a3 rezeptor agonisten
EP0889034A4 (de)	2001-06-06	Aminopyridin-derivate
SE8602449D0 (sv)	1986-05-29	11-beta substituted steroids and process for their preparation
ATE278678T1 (de)	2004-10-15	Substituierte 1-aza-2-imino-heterocyclen und ihre verwendung als aktivatoren der nikotinergen acetylcholinrezeptoren